Liraglutide biosimilar (Tonghua Dongbao) | Interleukin Related interleukin-related.com

Product Name :
Liraglutide biosimilar (Tonghua Dongbao)

Search keywords :
GLP-1R

drugId :
null

Target Vo:
Glucagon-like peptide 1 receptor

Target Vo Short Name :
GLP1R

Moa_Name:
Glucagon-like peptide 1 receptor agonists

First Approval Country :
Mainland China

First Approval Date Filter:
2023

Origin Company_Name :
Tonghua Dongbao Pharmaceutical Co Ltd

Active Company_Name :
Tonghua Dongbao Pharmaceutical Co Ltd

Active Indication_Name:
Diabetes Mellitus, Type 2

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Lenzilumab Description
FMRP Antibody manufacturer
Phospho-Acetyl Coenzyme A Carboxylase (Ser79) Antibody: Phospho-Acetyl Coenzyme A Carboxylase (Ser79) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 266 kDa, targeting to Phospho-Acetyl Coenzyme A Carboxylase (Ser79). It can be used for WB assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts